Hyperion DeFi AI Stock Analysis
Want to see HYPD full AI Analyst Report?
Hyperion DeFi (HYPD) AI Stock Analysis
Hyperion DeFi
(NASDAQ:HYPD)
The score is primarily constrained by weak cash-flow fundamentals and flagged earnings-quality/volatility concerns, despite a currently strong balance sheet. Technicals also weigh on the rating given the price is below all major moving averages with negative MACD. Offsetting these, the latest earnings call was constructive with reiterated improved guidance, early delivery of positive adjusted operating cash flow, debt repayment, and buybacks, but valuation signals are limited by a negative P/E and no dividend yield data.
Hyperion DeFi (HYPD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $41.23M
- Dividend Yield
- ―
- Average Volume (3M)
- 463.18K
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- 3.54
- Revenue Growth
- 452.71%
- EPS Growth
- 90.06%
- Country
- US
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Asset Management - Cryptocurrency
Hyperion DeFi Business Overview & Revenue Model
Company Description
Hyperion DeFi, Inc. is a U.S. publicly listed company that is building a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain. The company's primary objective is to provide shareholders with streamlined access to the H...
Hyperion DeFi Earnings Call Summary
The call was strongly positive, with record net income, substantial adjusted gross profit growth, positive core operating earnings and adjusted operating cash flow, lower operating expenses, full repayment of legacy debt, and progress across diversified DeFi revenue streams. The main negatives were the sequential decline in HYPE token holdings, lower adjusted EBITDA and treasury gains, variability in ecosystem rewards, remaining regulatory approval requirements, and the unresolved sports prediction-market opportunity.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Hyperion reiterated full year 2026 adjusted gross profit guidance of $7 million to $8 million, after originally guiding to $4 million to $6 million and raising it to $5 million to $7 million; through the first 9 months of the year, it had generated $4.9 million, roughly 70% of the low end of that range. Adjusted net operating cash flow was guided to flip positive by the end of '26, which the company said it delivered in Q3, while Q3 operating expenses, excluding stock-based compensation, were within the guided range of $2.0 million to $2.25 million and core operating earnings were above the guided $0 million to $0.5 million range. The company said costs will be completely gone beginning in Q4 for certain legal and biotech-exit items, aspires to continue to reduce costs, and does not expect costs to materially increase unless there's some sort of step-wise change in the scope of what it does.
Hyperion DeFi Financial Statement Overview
Summary
Balance sheet strength is a clear positive (very low leverage and large equity), but cash flow is a major concern with deeply negative TTM operating and free cash flow and a multi-year pattern of cash burn. Income statement shows a sharp TTM profitability swing, yet the cross-statement consistency and volatility flagged in the provided analysis reduce confidence in earnings quality.
Income Statement
58NeutralBalance Sheet
74PositiveCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.91M | 813.46K | 57.34K | 3,787 | 0 | 14.00M |
| Gross Profit | 1.61M | 510.17K | -3.87M | -12.22K | 0 | 12.40M |
| EBITDA | 40.06B | -43.76M | -46.21M | -24.11M | -26.32M | -12.17M |
| Net Income | 39.59B | -45.31M | -49.82M | -27.26M | -28.01M | -12.78M |
Balance Sheet | ||||||
| Total Assets | 146.29B | 51.76M | 3.67M | 28.78M | 31.04M | 31.66M |
| Cash, Cash Equivalents and Short-Term Investments | 6.62B | 6.44M | 2.12M | 14.85M | 22.86M | 19.46M |
| Total Debt | 529.31M | 8.51M | 11.24M | 16.08M | 10.12M | 7.15M |
| Total Liabilities | 4.20B | 10.70M | 16.76M | 19.78M | 13.80M | 11.19M |
| Stockholders Equity | 142.09B | 41.06M | -13.10M | 9.00M | 17.23M | 20.47M |
Cash Flow | ||||||
| Free Cash Flow | -8.77B | -14.77M | -30.28M | -27.81M | -25.98M | -22.49M |
| Operating Cash Flow | -8.76B | -14.77M | -30.12M | -23.84M | -25.11M | -20.87M |
| Investing Cash Flow | -4.92M | -71.95M | -161.48K | -3.97M | -874.75K | -1.62M |
| Financing Cash Flow | 16.34M | 91.05M | 17.55M | 19.79M | 21.51M | 21.46M |
Hyperion DeFi Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPD, the sentiment is Negative. The current price of 2.72 is below the 20-day moving average (MA) of 2.89, below the 50-day MA of 3.33, and below the 200-day MA of 3.34, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 42.52 is Neutral, neither overbought nor oversold. The STOCH value of 30.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYPD.
Hyperion DeFi Risk Analysis
Hyperion DeFi disclosed 48 risk factors in its most recent earnings report. Hyperion DeFi reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksHyperion DeFi Peers Comparison
Overall Rating
- HYPD56Neutral
SRTS54Neutral
TELA48Neutral
CTSO47Neutral
BDMD42Neutral
ICCM42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HYPD | 56Neutral | $42.11M | -0.72 | 111.28% | ― | 452.71% | 90.06% |
| SRTS | 54Neutral | $56.14M | -3.48 | -34.09% | ― | -53.40% | -1719.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TELA | 48Neutral | $42.56M | -1.10 | 425.91% | ― | 1.46% | 15.79% |
| CTSO | 47Neutral | $16.83M | -0.96 | -445.14% | ― | 8.64% | -61.01% |
| BDMD | 42Neutral | $3.33M | -0.19 | -48.23% | ― | ― | ― |
| ICCM | 42Neutral | $2.54M | -0.10 | -174.26% | ― | 41.62% | 20.47% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HYPD | Hyperion Defi, Inc. | 2.72 | -2.29 | -45.71% | |
| CTSO | Cytosorbents Corp | 5.37 | -7.83 | -59.32% | |
| SRTS | Sensus Healthcare, Inc. | 3.22 | -1.10 | -25.46% | |
| TELA | Tela Bio, Inc. | 0.86 | -0.14 | -14.00% | |
| ICCM | Icecure Medical Ltd. | 0.70 | -20.68 | -96.73% | |
| BDMD | Baird Medical Investment Holdings Ltd | 0.11 | -1.16 | -91.57% |
Hyperion DeFi Corporate Events
Hyperion DeFi Reports Record Quarterly Results and Debt Retirement
PositiveHyperion DeFi, a U.S. publicly listed decentralized-finance company building on Hyperliquid, reported results for the quarter ended September 30, 2026, on November 12, 2026. The company reported record net income of $39.6 million and adjusted EBITDA...
Hyperion DeFi Highlights Debt-Free Balance Sheet and Buybacks
PositiveOn September 28, 2026, Hyperion DeFi voluntarily repaid in full all outstanding obligations under its Avenue Capital loan agreement, terminating roughly $15 million in available term loan capacity and releasing all liens and security interests on its...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026